c-Kit (D816Y)

KIT · Variant type: point · HGVS: p.D816Y

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Avapritinib	99.9%	0.1%	97.73
2	Dasatinib	99.6%	0.4%	87.97
3	Nintedanib	98.8%	1.2%	90.23
4	Ripretinib	98.3%	1.7%	92.95
5	Ponatinib	96.7%	3.3%	78.23
6	Brigatinib	96.5%	3.5%	82.96
7	Bosutinib	96.2%	3.8%	87.22
8	Pralsetinib	95.9%	4.1%	93.43
9	Fostamatinib	95.2%	4.8%	96.74
10	Alectinib	94.3%	5.7%	95.49
11	Gilteritinib	94.2%	5.8%	88.97
12	Selpercatinib	93.9%	6.1%	96.72
13	Pacritinib	93.1%	6.9%	88.64
14	Mitapivat	90.2%	9.8%	100.00
15	Sunitinib	88.3%	11.7%	91.73
16	Pazopanib	87.8%	12.2%	97.49
17	Capivasertib	84.3%	15.7%	96.48
18	Vandetanib	80.3%	19.7%	95.74
19	Erdafitinib	78.2%	21.8%	95.71
20	Fedratinib	69.8%	30.2%	96.21
21	Tivozanib	69.2%	30.8%	92.42
22	Apatinib	68.6%	31.4%	97.73
23	Lenvatinib	67.0%	33.0%	97.74
24	Axitinib	64.7%	35.3%	93.23
25	Vemurafenib	64.3%	35.7%	96.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Avapritinib	99.9%	—	—
Dasatinib	99.6%	—	—
Nintedanib	98.8%	—	—
Ripretinib	98.3%	—	—
Ponatinib	96.7%	—	—
Brigatinib	96.5%	—	—
Bosutinib	96.2%	—	—
Pralsetinib	95.9%	—	—
Fostamatinib	95.2%	—	—
Alectinib	94.3%	—	—
Gilteritinib	94.2%	—	—
Selpercatinib	93.9%	—	—
Pacritinib	93.1%	—	—
Mitapivat	90.2%	—	—
Sunitinib	88.3%	—	—
Pazopanib	87.8%	—	—
Capivasertib	84.3%	—	—
Vandetanib	80.3%	—	—
Erdafitinib	78.2%	—	—
Fedratinib	69.8%	—	—
Tivozanib	69.2%	—	—
Apatinib	68.6%	—	—
Lenvatinib	67.0%	—	—
Axitinib	64.7%	—	—
Vemurafenib	64.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.8ms